CA2738081C - Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes - Google Patents

Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes Download PDF

Info

Publication number
CA2738081C
CA2738081C CA2738081A CA2738081A CA2738081C CA 2738081 C CA2738081 C CA 2738081C CA 2738081 A CA2738081 A CA 2738081A CA 2738081 A CA2738081 A CA 2738081A CA 2738081 C CA2738081 C CA 2738081C
Authority
CA
Canada
Prior art keywords
philadelphia
compound
compound according
negative myeloproliferative
histone deacetylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2738081A
Other languages
English (en)
French (fr)
Other versions
CA2738081A1 (en
Inventor
Tiziano Oldoni
Paolo Mascagni
Alessandro Rambaldi
Tiziano Barbui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of CA2738081A1 publication Critical patent/CA2738081A1/en
Application granted granted Critical
Publication of CA2738081C publication Critical patent/CA2738081C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2738081A 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes Active CA2738081C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2008A001720 2008-09-29
ITMI2008A001720A IT1392908B1 (it) 2008-09-29 2008-09-29 Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative
US19328308P 2008-11-13 2008-11-13
US61/193,283 2008-11-13
PCT/EP2009/062214 WO2010034693A1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Publications (2)

Publication Number Publication Date
CA2738081A1 CA2738081A1 (en) 2010-04-01
CA2738081C true CA2738081C (en) 2017-11-07

Family

ID=40810309

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2738081A Active CA2738081C (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Country Status (17)

Country Link
US (4) US20110294892A1 (https=)
EP (1) EP2344253B1 (https=)
JP (1) JP2012504112A (https=)
KR (3) KR20110069075A (https=)
CN (1) CN102164638A (https=)
BR (1) BRPI0913699A2 (https=)
CA (1) CA2738081C (https=)
CY (1) CY1115255T1 (https=)
DK (1) DK2344253T3 (https=)
ES (1) ES2478827T3 (https=)
HR (1) HRP20140499T1 (https=)
IT (1) IT1392908B1 (https=)
PL (1) PL2344253T3 (https=)
PT (1) PT2344253E (https=)
SI (1) SI2344253T1 (https=)
SM (1) SMT201400087B (https=)
WO (1) WO2010034693A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
US20180127386A1 (en) 2016-10-20 2018-05-10 Forma Therapeutics, Inc. Methods using hdac11 inhibitors
US10865328B2 (en) * 2017-02-20 2020-12-15 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2006063294A2 (en) * 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
CA2615574A1 (en) * 2005-07-29 2007-02-08 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
BRPI0619599A2 (pt) 2005-12-09 2011-10-11 Massachusetts Inst Technology método para inibir células de linhagem de tumor e para inibir o crescimento de tumores em um paciente
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2008082646A2 (en) * 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Also Published As

Publication number Publication date
EP2344253A1 (en) 2011-07-20
EP2344253B1 (en) 2014-04-23
CY1115255T1 (el) 2017-01-04
KR20110069075A (ko) 2011-06-22
BRPI0913699A2 (pt) 2017-06-13
HRP20140499T1 (hr) 2014-07-04
PT2344253E (pt) 2014-07-16
CA2738081A1 (en) 2010-04-01
IT1392908B1 (it) 2012-04-02
PL2344253T3 (pl) 2014-09-30
WO2010034693A1 (en) 2010-04-01
SI2344253T1 (sl) 2014-08-29
DK2344253T3 (da) 2014-06-16
US20140039059A1 (en) 2014-02-06
US20170049740A1 (en) 2017-02-23
US20210128512A1 (en) 2021-05-06
ITMI20081720A1 (it) 2010-03-30
US9522127B2 (en) 2016-12-20
JP2012504112A (ja) 2012-02-16
SMT201400087B (it) 2014-09-08
KR20160096721A (ko) 2016-08-16
CN102164638A (zh) 2011-08-24
US20110294892A1 (en) 2011-12-01
ES2478827T3 (es) 2014-07-23
KR20170124640A (ko) 2017-11-10

Similar Documents

Publication Publication Date Title
US20210128512A1 (en) Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
US20030235588A1 (en) Method of treating TRX mediated diseases
Huang et al. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment
ES2786925T3 (es) Composiciones y procedimientos para la expansión y el cultivo de células madre epiteliales
ES2981521T3 (es) Compuestos y procedimientos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales
BR112014001297B1 (pt) Composição farmacêutica em forma de tabletes de liberação prolongada contendo pirfenidona, seu processo de fabricação e uso de pirfenidona na regressão da insuficiência renal crônica, na contratura capsular mamária e na fibrose hepática
KR101514320B1 (ko) 신규한 암 예방 또는 치료용 약학적 조성물
US8217079B2 (en) Method for treating Philadelphia-negative myeloproliferative syndromes
JP2009504751A (ja) ヒストンデアセチラーゼ阻害薬の局所製剤及びその使用方法
ES2276829T3 (es) Derivados de acido benzoico y su utilizacion.
ES2972799T3 (es) Combinación farmacéutica de un compuesto de artemisinina, ácido 5-aminolevulínico o ácido metil-5-aminolevulínico y un agente quimioterapéutico
CN114366738A (zh) 雷帕霉素在促进神经干细胞扩增中的用途
ES3028375T3 (en) 1,2-dihydroquinoline-2-ones for their use in the treatment of limb-girdle muscular dystrophy
RU2847295C1 (ru) Фармацевтическая комбинация соединения артемизинина, 5- аминолевулиновой кислоты или метил-5-аминолевулиновой кислоты и химиотерапевтического агента
AU2008202913B2 (en) Method of Treating TRX Mediated Diseases
WO2011056542A1 (en) Cancer therapy with combinations of fts with hdac inhibitors
CN103599098B (zh) 姜黄素与银杏内酯b配伍组合物及其应用
ES2474765T3 (es) Agente profiláctico y/o terapéutico para la dismenorrea
WO2026006505A1 (en) Compounds as nlrp3 inhibitors and compositions and uses thereof
WO2015028673A1 (en) Cav3 CHANNEL BLOCKING AGENT FOR PAIN TREATMENT
ES2589169B1 (es) Uso de la pentoxifilina y de una composición farmacéutica para elaborar un medicamento para prevenir el envejecimiento prematuro en humanos
Guo et al. Mechanism of Activation of AMPK/P53-CyPD Signalling Pathway in Inhibiting Osteoblast Apoptosis Induced by Dexamethasone.
CN120392771A (zh) 小分子化合物及其在制备治疗24p3R介导的疾病的药物中的应用
Zhuang Articles in PresS. Am J Physiol Renal Physiol (July 29, 2009). doi: 10.1152/ajprenal. 00282.2009
Tsepkolenko Examining the Level of Interleukin-1 (IL-1) Production by Blood Mononuclear Cells During Treatment of Hyperplastic Skin Deteriorations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140717

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250912

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916